DIAGNOS Inc. (DGNOF)
OTCMKTS
· Delayed Price · Currency is USD
0.1790
-0.0057 (-3.09%)
Apr 24, 2025, 2:08 PM EDT
DIAGNOS Revenue
DIAGNOS had revenue of 26.04K CAD in the quarter ending December 31, 2024, a decrease of -50.04%. This brings the company's revenue in the last twelve months to 127.40K, down -35.15% year-over-year. In the fiscal year ending March 31, 2024, DIAGNOS had annual revenue of 170.16K, down -64.97%.
Revenue (ttm)
127.40K CAD
Revenue Growth
-35.15%
P/S Ratio
215.64
Revenue / Employee
5.79K CAD
Employees
22
Market Cap
19.09M USD
Revenue Chart
* This company reports financials in CAD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Mar 31, 2024 | 170.16K | -315.59K | -64.97% |
Mar 31, 2023 | 485.75K | 46.92K | 10.69% |
Mar 31, 2022 | 438.83K | 171.76K | 64.31% |
Mar 31, 2021 | 267.07K | -64.44K | -19.44% |
Mar 31, 2020 | 331.52K | 5.05K | 1.55% |
Mar 31, 2019 | Pro | Pro | Pro |
Mar 31, 2018 | Pro | Pro | Pro |
Mar 31, 2017 | Pro | Pro | Pro |
Mar 31, 2016 | Pro | Pro | Pro |
Mar 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
SS Innovations International | 20.65M |
Endo Inc. | 1.76B |
Veradigm | 588.02M |
Elite Pharmaceuticals | 70.00M |
Northwest Biotherapeutics | 1.38M |
Glass House Brands | 200.90M |
BioStem Technologies | 301.83M |
American Oncology Network | 1.76B |
DIAGNOS News
- 9 days ago - DIAGNOS Provides Additional Information on Amendment to Convertible Debentures - GlobeNewsWire
- 15 days ago - DIAGNOS Provides Update on its Health Canada Medical Device Licence Application - GlobeNewsWire
- 23 days ago - DIAGNOS amends terms of convertible debentures - Seeking Alpha
- 23 days ago - DIAGNOS Announces Amendment to Convertible Debentures - GlobeNewsWire
- 6 weeks ago - DIAGNOS is filing for the Saudi FDA Authorization of Its CARA SYSTEM, an AI Assisted Medical Device - GlobeNewsWire
- 7 weeks ago - DIAGNOS Announces Amendment to Convertible Debentures - GlobeNewsWire
- 2 months ago - DIAGNOS to File for FDA Pre-Market Authorization of Its AI-Powered CARA SYSTEM and Engages Ora as Regulatory Specialist - GlobeNewsWire
- 2 months ago - DIAGNOS to Present at Centurion One Capital 8th Annual Toronto Growth Conference - Newsfile Corp